Drug-Induced Acute Myocardial Infarction: Identifying 'Prime Suspects' from Electronic Healthcare Records-Based Surveillance System

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Coloma, Preciosa M ^a   Schuemie, Martijn J ^a   Trifirò, Gianluca ^a,b   Furlong, Laura ^c   van Mulligen, Erik ^a   Bauer Mehren, Anna ^c   Avillach, Paul ^d,e   Kors, Jan ^a   Sanz, Ferran ^c   Mestres, Jordi ^c   Oliveira, José Luis ^f   Boyer, Scott ^g   Helgee, Ernst Ahlberg ^g   Molokhia, Mariam ^h   Matthews, Justin ⁱ   Prieto Merino, David ⁱ   Gini, Rosa ^j   Herings, Ron ^k   Mazzaglia, Giampiero ^l   Picelli, Gino ^m   Scotti, Lorenza ⁿ   Pedersen, Lars ^o   van der Lei, Johan ^a   Sturkenboom, Miriam ^a   more..

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e AIX MARSEILLE UNIV   (France)

^f UNIVERSITY OF AVEIRO   (Portugal)

^g ASTRAZENECA R AND D   (Sweden)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^j Epidemiology Unit   (Italy)

^k PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^l Societa Italiana di Medicina Generale   (Italy)

^m Pedianet Societa' Servizi Telematici SRL   (Italy)

ⁿ UNIVERSITY OF MILANO BICOCCA   (Italy)

^o AARHUS UNIVERSITY HOSPITAL   (Denmark)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETAMETHASONE; CEFIXIME; CEFTRIAXONE; CISAPRIDE; CLARITHROMYCIN; CLONIDINE; DEXAMETHASONE; DOMPERIDONE; ERYTHROMYCIN; FENOTEROL; FENTANYL; FLUCONAZOLE; GLIBENCLAMIDE; KETOBEMIDONE; MAGALDRATE; MEGESTROL; METFORMIN; METOCLOPRAMIDE; NIFEDIPINE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PENICILLIN V; PIVAMPICILLIN; PREDNISONE; ROXITHROMYCIN; SALBUTAMOL; SULFONAMIDE; TRAMADOL; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ARTICLE; BIOLOGICAL PLAUSIBILITY; CLINICAL STUDY; CONFOUNDING VARIABLE; DEMOGRAPHY; DENMARK; DRUG EXPOSURE; DRUG INDUCED DISEASE; ELECTRONIC HEALTHCARE RECORDS BASED SURVEILLANCE SYSTEM; ELECTRONIC MEDICAL RECORD; EMERGENCY HEALTH SERVICE; FILTRATION; FOLLOW UP; HOSPITALIZATION; HUMAN; ITALY; LABORATORY TEST; MEDICAL LITERATURE; NETHERLANDS; NOVELTY; PRESCRIPTION; PUBLIC HEALTH; REIMBURSEMENT; STATISTICAL ANALYSIS; THREE TIER TRIAGE SYSTEM;

ACUTE DISEASE; ADVERSE DRUG REACTION REPORTING SYSTEMS; AZITHROMYCIN; BETAMETHASONE; CISAPRIDE; DOMPERIDONE; ELECTRONIC HEALTH RECORDS; FLUCONAZOLE; HUMANS; MEGESTROL ACETATE; METOCLOPRAMIDE; MYOCARDIAL INFARCTION;

EID: 84883144641     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072148     Document Type: Article

References (68)

1. Budnitz DS, Lovegrove MC, Shehab N, Richards CL, (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365: 2002-2012.
2. Hug BL, Keohane C, Seger DL, Yoon C, Bates DW, (2012) The costs of adverse drug events in community hospitals. Jt Comm J Qual Patient Saf 38: 120-126.
3. Wu TY, Jen MH, Bottle A, Molokhia M, Aylin P, et al. (2010) Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009. J R Soc Med 103: 239-250.
4. Black N, (1996) Why we need observational studies to evaluate the effectiveness of health care. BMJ 312: 1215-1218.
5. Papanikolaou PN, Christidi GD, Ioannidis JP, (2006) Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies. CMAJ 174: 635-641.
6. Ray WA, (2003) Population-based studies of adverse drug effects. N Engl J Med 349: 1592-1594.
7. Platt R, Wilson M, Chan KA, Benner JS, Marchibroda J, et al. (2009) The new Sentinel Network-improving the evidence of medical-product safety. N Engl J Med 361: 645-647.
8. Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, et al. (2011) Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf 20: 1-11.
9. Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, et al. (2010) Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med 153: 600-606.
10. The Uppsala Monitoring Centre. WHO Global Database Reaches 7 Million.
11. US Food and Drug Administration. Reports received and entered into AERS by year.
12. Meyboom RH, Lindquist M, Egberts AC, Edwards IR, (2002) Signal selection and follow-up in pharmacovigilance. Drug Saf 25: 459-465.
13. Waller P, Heeley E, Moseley J, (2005) Impact analysis of signals detected from spontaneous adverse drug reaction reporting data. Drug Saf 28: 843-850.
14. Heeley E, Waller P, Moseley J, (2005) Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study. Drug Saf 28: 901-906.
15. Levitan B, Yee CL, Russo L, Bayney R, Thomas AP, et al. (2008) A model for decision support in signal triage. Drug Saf 31: 727-735.
16. Lindquist M, (2007) Use of triage strategies in the WHO signal-detection process. Drug Saf 30: 635-637.
17. Mazzaglia G, Mantovani LG, Sturkenboom MC, Filippi A, Trifiro G, et al. (2005) Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 23: 2093-2100.
18. Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, et al. (1999) Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 38: 339-344.
19. Sturkenboom M, Nicolosi A, Cantarutti L, Mannino S, Picelli G, et al. (2005) Incidence of mucocutaneous reactions in children treated with niflumic acid, other nonsteroidal antiinflammatory drugs, or nonopioid analgesics. Pediatrics 116: e26-33.
20. Christensen S, Riis A, Norgaard M, Thomsen RW, Sorensen HT, (2007) Introduction of newer selective cyclo-oxygenase-2 inhibitors and rates of hospitalization with bleeding and perforated peptic ulcer. Aliment Pharmacol Ther 25: 907-912.
21. Goettsch WG, de Jong RB, Kramarz P, Herings RM, (2007) Developments of the incidence of osteoporosis in The Netherlands: a PHARMO study. Pharmacoepidemiol Drug Saf 16: 166-172.
22. Corrao G, Zambon A, Conti V, Nicotra F, La Vecchia C, et al. (2008) Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation. Ann Oncol 19: 150-155.
23. Barchielli A, Balzi D, Marchionni N, Carrabba N, Margheri M, et al. (2007) Early discharge after acute myocardial infarction in the current clinical practice. Community data from the AMI-Florence Registry, Italy. Int J Cardiol 114: 57-63.
24. Coloma PM, Trifiro G, Schuemie MJ, Gini R, Herings R, et al. (2012) Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf 21: 611-621.
25. Avillach P, Joubert M, Thiessard F, Trifiro G, Dufour JC, et al. (2010) Design and evaluation of a semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European EU-ADR project. Stud Health Technol Inform 160: 1085-1089.
26. Avillach P, Coloma PM, Gini R, Schuemie M, Mougin F, et al. (2013) Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. J Am Med Inform Assoc 20: 184-192.
27. Coloma PM, Valkhoff VE, Mazzaglia G, Nielsson MS, Pedersen L, et al. (2013) Identification of acute myocardial infarction from electronic healthcare records using different disease coding systems: a validation study in three European countries. BMJ Open 3.
28. Schuemie MJ, Coloma PM, Straatman H, Herings RM, Trifiro G, et al. (2012) Using Electronic Health Care Records for Drug Safety Signal Detection: A Comparative Evaluation of Statistical Methods. Med Care.
29. Schuemie MJ, (2011) Methods for drug safety signal detection in longitudinal observational databases: LGPS and LEOPARD. Pharmacoepidemiol Drug Saf 20: 292-299.
30. Bauer-Mehren A, van Mullingen EM, Avillach P, Carrascosa Mdel C, Garcia-Serna R, et al. (2012) Automatic filtering and substantiation of drug safety signals. PLoS Comput Biol 8: e1002457.
31. Oliveira JL, Lopes P, Nunes T, Campos D, Boyer S, et al. (2013) The EU-ADR Web Platform: delivering advanced pharmacovigilance tools. Pharmacoepidemiol Drug Saf 22: 459-467.
32. Hauben M, Aronson JK, (2009) Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 32: 99-110.
33. Hill AB, (1965) The Environment and Disease: Association or Causation? Proc R Soc Med 58: 295-300.
34. Caster O, Edwards IR, (2010) Reflections on attribution and decisions in pharmacovigilance. Drug Saf 33: 805-809.
35. Gurwitz D, Motulsky AG, (2007) 'Drug reactions, enzymes, and biochemical genetics': 50 years later. Pharmacogenomics 8: 1479-1484.
36. Stricker BH, Psaty BM, (2004) Detection, verification, and quantification of adverse drug reactions. BMJ 329: 44-47.
37. Evans M, Rees A, (2002) Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 25: 649-663.
38. Kounis NG, Zavras GM, (1991) Histamine-induced coronary artery spasm: the concept of allergic angina. Br J Clin Pract 45: 121-128.
39. Biteker M, (2010) Current understanding of Kounis syndrome. Expert Rev Clin Immunol 6: 777-788.
40. Kovanen PT, Kaartinen M, Paavonen T, (1995) Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92: 1084-1088.
41. Ridella M, Bagdure S, Nugent K, Cevik C, (2009) Kounis syndrome following beta-lactam antibiotic use: review of literature. Inflamm Allergy Drug Targets 8: 11-16.
42. Araujo L, Demoly P, (2008) Macrolides allergy. Curr Pharm Des 14: 2840-2862.
43. Thong BY, (2010) Update on the management of antibiotic allergy. Allergy Asthma Immunol Res 2: 77-86.
44. Demoly P, Gomes ER, (2005) Drug hypersensitivities: definition, epidemiology and risk factors. Eur Ann Allergy Clin Immunol 37: 202-206.
45. Rubin JB, Borden WB, (2012) Coronary heart disease in young adults. Curr Atheroscler Rep 14: 140-149.
46. Chen JP, Hou D, Pendyala L, Goudevenos JA, Kounis NG, (2009) Drug-eluting stent thrombosis: the Kounis hypersensitivity-associated acute coronary syndrome revisited. JACC Cardiovasc Interv 2: 583-593.
47. Keller GA, Di Girolamo G, (2010) Prokinetic agents and QT prolongation: a familiar scene with new actors. Curr Drug Saf 5: 73-78.
48. Quigley EM, (2011) Cisapride: what can we learn from the rise and fall of a prokinetic? J Dig Dis 12: 147-156.
49. Hennessy S, Leonard CE, Newcomb C, Kimmel SE, Bilker WB, (2008) Cisapride and ventricular arrhythmia. Br J Clin Pharmacol 66: 375-385.
50. Collins KK, Sondheimer JM, (2008) Domperidone-induced QT prolongation: add another drug to the list. J Pediatr 153: 596-598.
51. Tonini M, De Ponti F, Di Nucci A, Crema F, (1999) Review article: cardiac adverse effects of gastrointestinal prokinetics. Aliment Pharmacol Ther 13: 1585-1591.
52. Mosca L, Banka CL, Benjamin EJ, Berra K, Bushnell C, et al. (2007) Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol 49: 1230-1250.
53. Stone N, (1994) Secondary causes of hyperlipidemia. Med Clin North Am 78: 117-141.
54. Sarnes E, Crofford L, Watson M, Dennis G, Kan H, et al. (2011) Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther 33: 1413-1432.
55. Weeke P, Folke F, Gislason GH, Lippert FK, Olesen JB, et al. (2010) Pharmacotherapy and hospital admissions before out-of-hospital cardiac arrest: a nationwide study. Resuscitation 81: 1657-1663.
56. Gisondi P, Girolomoni G, (2009) Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost 35: 313-324.
57. Szekanecz Z, Kerekes G, Der H, Sandor Z, Szabo Z, et al. (2007) Accelerated atherosclerosis in rheumatoid arthritis. Ann N Y Acad Sci 1108: 349-358.
58. Panwalker AP, (1992) Hyperglycemia induced by megestrol acetate. Ann Intern Med 116: 878.
59. Henry K, Rathgaber S, Sullivan C, McCabe K, (1992) Diabetes mellitus induced by megestrol acetate in a patient with AIDS and cachexia. Ann Intern Med 116: 53-54.
60. Kilby JM, Tabereaux PB, (1998) Severe hyperglycemia in an HIV clinic: preexisting versus drug-associated diabetes mellitus. J Acquir Immune Defic Syndr Hum Retrovirol 17: 46-50.
61. Khazan M, Mathis AS, (2002) Probable case of torsades de pointes induced by fluconazole. Pharmacotherapy 22: 1632-1637.
62. McMahon JH, Grayson ML, (2008) Torsades de pointes in a patient receiving fluconazole for cerebral cryptococcosis. Am J Health Syst Pharm 65: 619-623.
63. Sharkey PK, Rinaldi MG, Dunn JF, Hardin TC, Fetchick RJ, et al. (1991) High-dose itraconazole in the treatment of severe mycoses. Antimicrob Agents Chemother 35: 707-713.
64. Ahmad SR, Singer SJ, Leissa BG, (2001) Congestive heart failure associated with itraconazole. Lancet 357: 1766-1767.
65. Groll AH, Piscitelli SC, Walsh TJ, (1998) Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv Pharmacol 44: 343-500.
66. Brüggemann RJ AJ, Blijlevens NM, Billaud EM, Kosterink JG, Verweij PE, et al. (2009) Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48: 1441-1458.
67. Edwards IR, Aronson JK, (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356: 1255-1259.
68. Park BK, Kitteringham NR, Powell H, Pirmohamed M, (2000) Advances in molecular toxicology-towards understanding idiosyncratic drug toxicity. Toxicology 153: 39-60.